357
Participants
Start Date
September 5, 2018
Primary Completion Date
May 25, 2021
Study Completion Date
May 25, 2021
daxibotulinumtoxinA for injection
DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
Mount Sinai Movement Disorders Center, New York
Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn
Neurologicka klinika 1. LF UK a VFN v Praze, Prague
University of Rochester, Rochester
University of Pennsylvania, Philadelphia
Wake Forest Health Sciences, Winston-Salem
Duke University, Durham
Hospital Universitario de La Princesa, Madrid
Coastal Neurology, Port Royal
CHU Caremeau, Nîmes
Emory University, Atlanta
Neurologisches Studienzentrum Universitätsklinik für Neurologie Innsbruck, Innsbruck
Marta Dagmara BANACH Marta Banach Specjalistyczny Gabinet Neurologiczny, Krakow
Medizinische Hochschule Hannover, Hanover
Krakowska Akademia Neurologii Sp. z o.o., Krakow
University of Florida Center for Movement Disorders and Neurorestoration, Gainesville
Infinity Clinical research, Hollywood
University of Miami, Miami
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
USF Parkinson's Disease and Movement Disorders Center, Tampa
Suncoast Neuroscience Associates, St. Petersburg
Vanderbilt University Medical Center, Nashville
Intrafusion Research Network - Wesley Neurology Clinic, Cordova
CHU de Grenoble, Grenoble
Veracity Neuroscience LLC, Memphis
Universitaetsklinikum Duesseldorf, Düsseldorf
Henry Ford West Bloomfield Hospital, West Bloomfield
QUEST Research Institute, Farmington
Michigan State University, East Lansing
Vestra Clinics s.r.o., Rychnov nad Kněžnou
Nemocnice Pardubickeho kraje, a.s.; Pardubicka nemocnice, Pardubice
GFO Kliniken Troisdorf, Betriebsstätte St. Johannes Sieglar, Troisdorf
Hôpital Roger Salengro, Lille
Rush University Medical Center, Chicago
St Louis University, St Louis
Washington University, St Louis
University of Nebraska Medical Center, Omaha
Hôpital Neurologique Pierre Wertheimer, Bron
Fakultní nemocnice Ostrava, Ostrava-Poruba
Universitätsklinikum Tübingen, Tübingen
Texas Neurology. P.A., Dallas
Baylor College of Medicine, Houston
Houston Methodist Neurological Institute, Houston
Central Texas Neurology Consultants, Round Rock
Rocky Mountain Movement Disorders Center, Englewood
Szpital sw. Wojciecha Podmiot Leczniczy Copernicus Sp. Z o.o., Gdansk
Klinikum rechts der Isar der TUM, München
HOPE Research Institute, Phoenix
Movement Disorders Center of Arizona, Scottsdale
USC Keck School of Medicine, Los Angeles
Care Access Research LLC, Pasadena
Loma Linda University, Loma Linda
The Parkinsons and Movement Disorder Institute, Fountain Valley
Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford
Kansas Institute of Research, Overland Park
The University of Vermont Medical Center, Burlington
University Health Network, Toronto Western Hospital, Toronto
Centrum Medyczne Pratia Warszawa, Warsaw
Mazovian Brodno Hospital, Warsaw
Hospital Universitari Vall d'Hebron, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitario Burgos, Burgos
Royal Devon and Exeter Foundation Trust Hospital, Exeter
The Walton Centre NHS Foundation Trust, Neuroscience Research Centre, Liverpool
Salford Royal NHS Foundation Trust, Salford
Collaborators (1)
Revance Therapeutics, Inc.
INDUSTRY
Syneos Health
OTHER